Cancer vaccines inducing antibody production: more pros than cons

References

• Plymoth A, Viviani S, Hainaut P. Control of hepatocellular carcinoma through hepatitis B vaccination in areas of high endemicity: perspectives for global liver cancer prevention. Cancer Lett.286(1), 15–21 (2009).
   PubMed Web of Science ®Google Scholar
• Schiller JT, Lowy DR. Prospects for cervical cancer prevention by human papillomavirus vaccination. Cancer Res.66(21), 10229–10232 (2006).
   PubMed Web of Science ®Google Scholar
• Suzich JA, Ghim SJ, Palmer-Hill FJ et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc. Natl Acad. Sci. USA92(25), 11553–11557 (1995).
   PubMed Web of Science ®Google Scholar
• Bergman PJ, Camps-Palau MA, Mcknight JA et al. Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the animal medical center. Vaccine24(21), 4582–4585 (2006).
   PubMed Web of Science ®Google Scholar
• Bilusic M, Madan RA. Therapeutic cancer vaccines: the latest advancement in targeted therapy. Am. J. Ther. DOI: 10.1097/MJT.0b013e3182068cdb (2011) (Epub ahead of print).
   Google Scholar
• Monzavi-Karbassi B, Artaud C, Jousheghany F et al. Reduction of spontaneous metastases through induction of carbohydrate cross-reactive apoptotic antibodies. J. Immunol.174(11), 7057–7065 (2005).
   PubMed Web of Science ®Google Scholar
• The future of monoclonal antibodies therapeutics: innovation in antibody engineering, key growth strategies and forecasts to 2011. Business Insights (2006).
   Google Scholar
• Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJ. The safety and side effects of monoclonal antibodies. Nat. Rev. Drug Discov.9(4), 325–338 (2010).
   PubMed Web of Science ®Google Scholar
• Siena S, Glynne-Jones R, Adenis A et al. Reduced incidence of infusion-related reactions in metastatic colorectal cancer during treatment with cetuximab plus irinotecan with combined corticosteroid and antihistamine premedication. Cancer116(7), 1827–1837 (2010).
   PubMed Web of Science ®Google Scholar
• Schwartzberg LS, Stepanski EJ, Fortner BV, Houts AC. Retrospective chart review of severe infusion reactions with rituximab, cetuximab, and bevacizumab in community oncology practices: assessment of clinical consequences. Support Care Cancer16(4), 393–398 (2008).
   PubMed Web of Science ®Google Scholar
• Chung CH, Mirakhur B, Chan E et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1,3-galactose. N. Engl. J. Med.358(11), 1109–1117 (2008).
   PubMed Web of Science ®Google Scholar
• Sorensen RU, Leiva LE, Giangrosso PA et al. Response to a heptavalent conjugate Streptococcus pneumoniae vaccine in children with recurrent infections who are unresponsive to the polysaccharide vaccine. Pediatr. Infect. Dis. J.17(8), 685–691 (1998).
   PubMed Web of Science ®Google Scholar
• Kaine JL, Kivitz AJ, Birbara C, Luo AY. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J. Rheumatol.34(2), 272–279 (2007).
   PubMed Web of Science ®Google Scholar
• Lai CC, Lee LN, Yu CJ et al. Antibody responses to pneumococcal polysaccharide vaccine in Taiwanese patients with chronic obstructive pulmonary disease. J. Formos. Med. Assoc.106(3), 196–203 (2007).
   PubMed Web of Science ®Google Scholar
• Schauer U, Stemberg F, Rieger Ch et al. Levels of antibodies specific to tetanus toxoid, Haemophilus influenzae type b, and pneumococcal capsular polysaccharide in healthy children and adults. Clin. Diagn. Lab Immunol.10(2), 202–207 (2003).
   PubMedGoogle Scholar
• Gentili G, D’amelio R, Wirz M et al. Prevalence of hyperimmunization against tetanus in Italians born after the introduction of mandatory vaccination of children with tetanus toxoid in 1968. Infection21(2), 80–82 (1993).
   PubMed Web of Science ®Google Scholar
• Amos SM, Duong CP, Westwood JA et al. Autoimmunity associated with immunotherapy of cancer. Blood118(3), 499–509 (2011).
   PubMed Web of Science ®Google Scholar
• Finn OO, Banchereau J. Cancer vaccines: the state of the art. Semin. Immunol.22(3), 103–104 (2010).
   PubMed Web of Science ®Google Scholar
• Ryan SO, Turner MS, Gariepy J, Finn OJ. Tumor antigen epitopes interpreted by the immune system as self or abnormal-self differentially affect cancer vaccine responses. Cancer Res.70(14), 5788–5796 (2010).
   PubMed Web of Science ®Google Scholar
• Farkas AM, Finn OJ. Vaccines based on abnormal self-antigens as tumor-associated antigens: immune regulation. Semin. Immunol.22(3), 125–131 (2010).
   PubMed Web of Science ®Google Scholar
• Caspi RR. Immunotherapy of autoimmunity and cancer: the penalty for success. Nat. Rev. Immunol.8(12), 970–976 (2008).
   PubMed Web of Science ®Google Scholar
• Correale P, Fioravanti A, Bertoldi I, Montagnani F, Miracco C, Francini G. Occurrence of autoimmunity in a long-term survivor with metastatic colon carcinoma treated with a new chemo-immunotherapy regimen. J. Chemotherapy20(2), 278–281 (2008).
   PubMed Web of Science ®Google Scholar
• Towns K, Bedard PL, Verma S. Matters of the heart: cardiac toxicity of adjuvant systemic therapy for early-stage breast cancer. Curr. Oncol.15, S16–S29 (2008).
   Google Scholar
• Mcbride WH, Chiang CS, Olson JL et al. Failla memorial lecture – a sense of danger from radiation. Radiat. Res.162(1), 1–19 (2004).
   PubMed Web of Science ®Google Scholar
• Smyth PP, Shering SG, Kilbane MT et al. Serum thyroid peroxidase autoantibodies, thyroid volume, and outcome in breast carcinoma. J. Clin. Endocrinol. Metab.83(8), 2711–2716 (1998).
   PubMed Web of Science ®Google Scholar
• Kilbane M, Shering S, Symith D, Mcdermott E, O’higgins N, Symith P. Thyroid peroxidase (TPO): an autoantigen common to the thyroid and breast. J. Endocrinol.156, 323 (1998).
   PubMed Web of Science ®Google Scholar
• Bouwhuis MG, Ten Hagen TL, Suciu S, Eggermont AM. Autoimmunity and treatment outcome in melanoma. Curr. Opin. Oncol.23(2), 170–176 (2011).
   PubMed Web of Science ®Google Scholar
• Pardoll DM. Inducing autoimmune disease to treat cancer. Proc. Natl Acad. Sci. USA96(10), 5340–5342 (1999).
   PubMed Web of Science ®Google Scholar
• Gogas H, Ioannovich J, Dafni U et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N. Engl. J. Med.354(7), 709–718 (2006).
   PubMed Web of Science ®Google Scholar
• Lute KD, May KF Jr, Lu P et al. Human CTLA4 knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti-CTLA-4 antibodies. Blood106(9), 3127–3133 (2005).
   PubMed Web of Science ®Google Scholar
• Greiner JW, Zeytin H, Anver MR, Schlom J. Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity. Cancer Res.62(23), 6944–6951 (2002).
   PubMed Web of Science ®Google Scholar
• Wang LXJ, Westwood JA, Moeller M et al. Tumor ablation by gene-modified T cells in the absence of autoimmunity. Cancer Res.70(23), 9591–9598 (2010).
   PubMed Web of Science ®Google Scholar
• Petkova SB, Akilesh S, Sproule TJ et al. Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. Int. Immunol.18(12), 1759–1769 (2006).
   PubMed Web of Science ®Google Scholar
• Shields RL, Namenuk AK, Hong K et al. High resolution mapping of the binding site on human IgG1 for Fc γ RI, Fc γ RII, Fc γ RIII, and FcRn and design of IgG1 variants with improved binding to the Fc γ R. J. Biol. Chem.276(9), 6591–6604 (2001).
   PubMed Web of Science ®Google Scholar
• Hudis CA. Trastuzumab – mechanism of action and use in clinical practice. N. Engl. J. Med.357(1), 39–51 (2007).
   PubMed Web of Science ®Google Scholar
• Matter-Walstra KW, Dedes KJ, Schwenkglenks M, Brauchli P, Szucs TD, Pestalozzi BC. Trastuzumab beyond progression: a cost-utility analysis. Ann. Oncol.21(11), 2161–2168 (2010).
   PubMed Web of Science ®Google Scholar
• Giantonio BJ, Catalano PJ, Meropol NJ et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the eastern cooperative oncology group study E3200. J. Clin. Oncol.25(12), 1539–1544 (2007).
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med.363(5), 411–422 (2010).
   PubMed Web of Science ®Google Scholar
• Carballido E, Fishman M. Sipuleucel-T: prototype for development of anti-tumor vaccines. Curr. Oncol. Rep.13(2), 112–119 (2011).
   PubMed Web of Science ®Google Scholar
• Romano E, Rossi M, Ratzinger G et al. Peptide-loaded langerhans cells, despite increased IL15 secretion and T cell activation in vitro, elicit anti-tumor T cell responses comparable to peptide-loaded monocyte-derived dendritic cells in vivo. Clin. Cancer. Res.17(7), 1984–1997 (2011).
   PubMed Web of Science ®Google Scholar
• Wang SJ. The state of art patent search with an example of human vaccines. Hum. Vaccine7(2), 265–268 (2011).
   PubMed Web of Science ®Google Scholar
• Plotkin SA. Vaccines: past, present and future. Nat. Med.11(4), S5–S11 (2005).
   PubMed Web of Science ®Google Scholar
• Mccullers JA. Evolution, benefits, and shortcomings of vaccine management. J. Manag. Care Pharm.13(Suppl. 7B), S2–S6 (2007).
   Google Scholar
• Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature256(5517), 495–497 (1975).
   PubMed Web of Science ®Google Scholar
• Reichert JM, Wenger JB. Development trends for new cancer therapeutics and vaccines. Drug Discov. Today13(1–2), 30–37 (2008).
   PubMed Web of Science ®Google Scholar
• Dechant M, Beyer T, Schneider-Merck T et al. Effector mechanisms of recombinant IgA antibodies against epidermal growth factor receptor. J. Immunol.179(5), 2936–2943 (2007).
   PubMed Web of Science ®Google Scholar
• Otten MA, Rudolph E, Dechant M et al. Immature neutrophils mediate tumor cell killing via IgA but not IgG Fc receptors. J. Immunol.174(9), 5472–5480 (2005).
   PubMed Web of Science ®Google Scholar
• Fu SL, Pierre J, Smith-Norowitz TA et al. Immunoglobulin E antibodies from pancreatic cancer patients mediate antibody-dependent cell-mediated cytotoxicity against pancreatic cancer cells. Clin. Exp. Immunol.153(3), 401–409 (2008).
   PubMed Web of Science ®Google Scholar
• Karagiannis P, Singer J, Hunt J et al. Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells. Cancer Immunol. Immunother.58(6), 915–930 (2009).
   PubMed Web of Science ®Google Scholar
• Jensen-Jarolim E, Achatz G, Turner MC et al. AllergoOncology: the role of IgE-mediated allergy in cancer. Allergy63(10), 1255–1266 (2008).
   PubMed Web of Science ®Google Scholar
• Brunner R, Jensen-Jarolim E, Pali-Scholl I. The ABC of clinical and experimental adjuvants – a brief overview. Immunol. Lett.128(1), 29–35 (2010).
   PubMed Web of Science ®Google Scholar
• Riemer AB, Klinger M, Wagner S et al. Generation of peptide mimics of the epitope recognized by trastuzumab on the oncogenic protein Her-2/neu. J. Immunol.173(1), 394–401 (2004).
   PubMed Web of Science ®Google Scholar
• Riemer AB, Untersmayr E, Knittelfelder R et al. Active induction of tumor-specific IgE antibodies by oral mimotope vaccination. Cancer Res.67(7), 3406–3411 (2007).
   PubMed Web of Science ®Google Scholar
• Cecco S, Muraro E, Giacomin E et al. Cancer vaccines in Phase II/III clinical trials: state of the art and future perspectives. Curr. Cancer Drug Targets11(1), 85–102 (2010).
   Web of Science ®Google Scholar
• Harwerth IM, Wels W, Schlegel J, Muller M, Hynes NE. Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth. Br. J. Cancer68(6), 1140–1145 (1993).
   PubMed Web of Science ®Google Scholar
• Hurwitz E, Stancovski I, Sela M, Yarden Y. Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake. Proc. Natl Acad. Sci. USA92(8), 3353–3357 (1995).
   PubMed Web of Science ®Google Scholar
• Yip YL, Smith G, Koch J, Dubel S, Ward RL. Identification of epitope regions recognized by tumor inhibitory and stimulatory anti-ErbB-2 monoclonal antibodies: implications for vaccine design. J. Immunol.166(8), 5271–5278 (2001).
   PubMed Web of Science ®Google Scholar
• Wiedermann U, Wiltschke C, Jasinska J et al. A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a Phase I study. Breast Cancer Res. Treat.119(3), 673–683 (2010).
   PubMed Web of Science ®Google Scholar
• Zhao L, Liu Z, Fan D. Overview of mimotopes and related strategies in tumor vaccine development. Expert Rev. Vaccines7(10), 1547–1555 (2008).
   PubMed Web of Science ®Google Scholar
• Riemer AB, Kurz H, Klinger M, Scheiner O, Zielinski CC, Jensen-Jarolim E. Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies. J. Natl Cancer Inst.97(22), 1663–1670 (2005).
   PubMed Web of Science ®Google Scholar
• Hartmann C, Muller N, Blaukat A, Koch J, Benhar I, Wels WS. Peptide mimotopes recognized by antibodies cetuximab and matuzumab induce a functionally equivalent anti-EGFR immune response. Oncogene29(32), 4517–4527 (2010).
   PubMed Web of Science ®Google Scholar
• Yang L, Jiang H, Shi B et al. Identification and characterization of Ch806 mimotopes. Cancer Immunol. Immunother.59(10), 1481–1487 (2010).
   PubMed Web of Science ®Google Scholar
• Witsch EJ, Mahlknecht G, Wakim J et al. Generation and characterization of peptide mimotopes specific for anti ErbB-2 monoclonal antibodies. Int. Immunol.23(6), 391–403 (2011).
   PubMed Web of Science ®Google Scholar
• Jiang B, Liu W, Qu H et al. A novel peptide isolated from a phage display peptide library with trastuzumab can mimic antigen epitope of HER-2. J. Biol. Chem.280(6), 4656–4662 (2005).
   PubMed Web of Science ®Google Scholar
• Vaisman N, Nissim A, Klapper LN, Tirosh B, Yarden Y, Sela M. Specific inhibition of the reaction between a tumor-inhibitory antibody and the ErbB-2 receptor by a mimotope derived from a phage display library. Immunol. Lett.75(1), 61–67 (2000).
   PubMed Web of Science ®Google Scholar
• Bramswig KH, Knittelfelder R, Gruber S et al. Immunization with mimotopes prevents growth of carcinoembryonic antigen positive tumors in BALB/c mice. Clin. Cancer Res.13(21), 6501–6508 (2007).
   PubMed Web of Science ®Google Scholar
• Meng FP, Ding J, Yu ZC et al. Oral attenuated Salmonella typhimurium vaccine against MG7-Ag mimotope of gastric cancer. World J. Gastroenterol.11(12), 1833–1836 (2005).
   PubMed Web of Science ®Google Scholar
• Riemer AB, Hantusch B, Sponer B et al. High-molecular-weight melanoma-associated antigen mimotope immunizations induce antibodies recognizing melanoma cells. Cancer Immunol. Immunother.54(7), 677–684 (2005).
   PubMed Web of Science ®Google Scholar
• Luo W, Ko E, Hsu JC, Wang X, Ferrone S. Targeting melanoma cells with human high molecular weight-melanoma associated antigen-specific antibodies elicited by a peptide mimotope: functional effects. J. Immunol.176(10), 6046–6054 (2006).
   PubMed Web of Science ®Google Scholar
• Wagner S, Krepler C, Allwardt D et al. Reduction of human melanoma tumor growth in severe combined immunodeficient mice by passive transfer of antibodies induced by a high molecular weight melanoma-associated antigen mimotope vaccine. Clin. Cancer Res.14(24), 8178–8183 (2008).
   PubMed Web of Science ®Google Scholar
• Perosa F, Favoino E, Vicenti C et al. Two structurally different rituximab-specific CD20 mimotope peptides reveal that rituximab recognizes two different CD20-associated epitopes. J. Immunol.182(1), 416–423 (2009).
   PubMed Web of Science ®Google Scholar
• Riemer AB, Forster-Waldl E, Bramswig KH et al. Induction of IgG antibodies against the GD2 carbohydrate tumor antigen by vaccination with peptide mimotopes. Eur. J. Immunol.36(5), 1267–1274 (2006).
   PubMed Web of Science ®Google Scholar
• Fest S, Huebener N, Weixler S et al. Characterization of GD2 peptide mimotope DNA vaccines effective against spontaneous neuroblastoma metastases. Cancer Res.66(21), 10567–10575 (2006).
   PubMed Web of Science ®Google Scholar
• Wierzbicki A, Gil M, Ciesielski M et al. Immunization with a mimotope of GD2 ganglioside induces CD8+ T cells that recognize cell adhesion molecules on tumor cells. J. Immunol.181(9), 6644–6653 (2008).
   PubMed Web of Science ®Google Scholar
• Gil M, Bieniasz M, Wierzbicki A, Bambach BJ, Rokita H, Kozbor D. Targeting a mimotope vaccine to activating Fc γ receptors empowers dendritic cells to prime specific CD8+ T cell responses in tumor-bearing mice. J. Immunol.183(10), 6808–6818 (2009).
   PubMed Web of Science ®Google Scholar
• Kozbor D. Cancer vaccine with mimotopes of tumor-associated carbohydrate antigens. Immunol. Res.46(1–3), 23–31 (2010).
   PubMed Web of Science ®Google Scholar
• Hafner C, Wagner S, Jasinska J et al. Epitope-specific antibody response to Mel-CAM induced by mimotope immunization. J. Invest. Dermatol.124(1), 125–131 (2005).
   PubMed Web of Science ®Google Scholar
• Shanmugam A, Suriano R, Chaudhuri D et al. Identification of PSA peptide mimotopes using phage display peptide library. Peptides32(6), 1097–1102 (2011).
   PubMed Web of Science ®Google Scholar
• Ru B, Huang J, Dai P et al. MimoDB: a new repository for mimotope data derived from phage display technology. Molecules15(11), 8279–8288 (2010).
   PubMed Web of Science ®Google Scholar
• Forster-Waldl E, Riemer AB, Dehof AK et al. Isolation and structural analysis of peptide mimotopes for the disialoganglioside GD2, a neuroblastoma tumor antigen. Mol. Immunol.42(3), 319–325 (2005).
   PubMed Web of Science ®Google Scholar
• Chen Y, Wu K, Guo C et al. A novel DNA vaccine containing four mimicry epitopes for gastric cancer. Cancer Biol. Ther.4(3), 308–312 (2005).
   PubMed Web of Science ®Google Scholar
• Lin T, Liang S, Meng F et al. Enhanced immunogenicity and antitumour effects with heterologous prime–boost regime using vaccines based on MG7-Ag mimotope of gastric cancer. Clin. Exp. Immunol.144(2), 319–325 (2006).
   PubMed Web of Science ®Google Scholar
• Kowalczyk A, Wierzbicki A, Gil M et al. Induction of protective immune responses against NXS2 neuroblastoma challenge in mice by immunotherapy with GD2 mimotope vaccine and IL-15 and IL-21 gene delivery. Cancer Immunol. Immunother.56(9), 1443–1458 (2007).
   PubMed Web of Science ®Google Scholar
• Bolesta E, Kowalczyk A, Wierzbicki A et al. DNA vaccine expressing the mimotope of GD2 ganglioside induces protective GD2 cross-reactive antibody responses. Cancer Res.65(8), 3410–3418 (2005).
   PubMed Web of Science ®Google Scholar
• Riemer AB, Kraml G, Scheiner O, Zielinski CC, Jensen-Jarolim E. Matching of trastuzumab (Herceptin) epitope mimics onto the surface of Her-2/neu – a new method of epitope definition. Mol. Immunol.42(9), 1121–1124 (2005).
   PubMed Web of Science ®Google Scholar
• Knittelfelder R, Riemer AB, Jensen-Jarolim E. Mimotope vaccination – from allergy to cancer. Expert Opin. Biol. Ther.9(4), 493–506 (2009).
   PubMed Web of Science ®Google Scholar
• Linnemann T, Tumenjargal S, Gellrich S et al. Mimotopes for tumor-specific T lymphocytes in human cancer determined with combinatorial peptide libraries. Eur. J. Immunol.31(1), 156–165 (2001).
   PubMed Web of Science ®Google Scholar
• Tumenjargal S, Gellrich S, Linnemann T et al. Anti-tumor immune responses and tumor regression induced with mimotopes of a tumor-associated T cell epitope. Eur. J. Immunol.33(11), 3175–3185 (2003).
   PubMed Web of Science ®Google Scholar
• Sharav T, Wiesmuller KH, Walden P. Mimotope vaccines for cancer immunotherapy. Vaccine25(16), 3032–3037 (2007).
   PubMed Web of Science ®Google Scholar
• Van Stipdonk MJ, Badia-Martinez D, Sluijter M, Offringa R, Van Hall T, Achour A. Design of agonistic altered peptides for the robust induction of CTL directed towards H-2Db in complex with the melanoma-associated epitope gp100. Cancer Res.69(19), 7784–7792 (2009).
   PubMed Web of Science ®Google Scholar
• Hashiguchi S, Yamaguchi Y, Takeuchi O, Akira S, Sugimura K. Immunological basis of M13 phage vaccine: regulation under MyD88 and TLR9 signaling. Biochem. Biophys. Res. Commun.402(1), 19–22 (2010).
   PubMed Web of Science ®Google Scholar
• Scholl I, Wiedermann U, Forster-Waldl E et al. Phage-displayed Bet mim 1, a mimotope of the major birch pollen allergen Bet v 1, induces B cell responses to the natural antigen using bystander T cell help. Clin. Exp. Allergy32(11), 1583–1588 (2002).
   PubMedGoogle Scholar
• Monzavi-Karbassi B, Pashov A, Jousheghany F, Artaud C, Kieber-Emmons T. Evaluating strategies to enhance the anti-tumor immune response to a carbohydrate mimetic peptide vaccine. Int. J. Mol. Med.17(6), 1045–1052 (2006).
   PubMed Web of Science ®Google Scholar
• Gameiro SR, Caballero JA, Higgins JP, Apelian D, Hodge JW. Exploitation of differential homeostatic proliferation of T-cell subsets following chemotherapy to enhance the efficacy of vaccine-mediated antitumor responses. Cancer Immunol. Immunother. DOI: 10.1007/s00262-011-1020-8 (2011) (Epub ahead of print).
   PubMedGoogle Scholar
• Pickford WJ, Watson AJ, Barker RN. Different forms of helper tolerance to carcinoembryonic antigen: ignorance and regulation. Clin. Cancer Res.13(15 Pt 1), 4528–4537 (2007).
   PubMed Web of Science ®Google Scholar
• Mahipal A, Terai M, Berd D et al. Tumor-derived interleukin-10 as a prognostic factor in stage III patients undergoing adjuvant treatment with an autologous melanoma cell vaccine. Cancer Immunol. Immunother.60(7), 1039–1045 (2011).
   PubMed Web of Science ®Google Scholar
• Gross S, Geldmacher A, Sharav T, Losch F, Walden P. Immunosuppressive mechanisms in cancer: consequences for the development of therapeutic vaccines. Vaccine27(25–26), 3398–3400 (2009).
   PubMed Web of Science ®Google Scholar
• Degl’innocenti E, Grioni M, Capuano G et al. Peripheral T-cell tolerance associated with prostate cancer is independent from CD4+CD25+ regulatory T cells. Cancer Res.68(1), 292–300 (2008).
   PubMed Web of Science ®Google Scholar
• Sharma MD, Hou DY, Baban B et al. Reprogrammed foxp3(+) regulatory T cells provide essential help to support cross-presentation and CD8(+) T cell priming in naive mice. Immunity33(6), 942–954 (2010).
   PubMed Web of Science ®Google Scholar
• Munn DH, Sharma MD, Hou D et al. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J. Clin. Invest.114(2), 280–290 (2004).
   PubMed Web of Science ®Google Scholar
• Sharma MD, Baban B, Chandler P et al. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J. Clin. Invest.117(9), 2570–2582 (2007).
   PubMed Web of Science ®Google Scholar
• Perosa F, Favoino E, Vicenti C, Merchionne F, Dammacco F. Identification of an antigenic and immunogenic motif expressed by two 7-mer rituximab-specific cyclic peptide mimotopes: implication for peptide-based active immunotherapy. J. Immunol.179(11), 7967–7974 (2007).
   PubMed Web of Science ®Google Scholar
• Riemer A, Scheiner O, Jensen-Jarolim E. Allergen mimotopes. Methods32(3), 321–327 (2004).
   PubMed Web of Science ®Google Scholar
• Latzka J, Gaier S, Hofstetter G et al. Specificity of mimotope-induced anti-high molecular weight-melanoma associated antigen (HMW-MAA) antibodies does not ensure biological activity. PLoS One6(5), e19383 (2011).
   PubMed Web of Science ®Google Scholar
• Schijns VE, Lavelle EE. Trends in vaccine adjuvants. Expert Rev. Vaccines10(4), 539–550 (2011).
   PubMed Web of Science ®Google Scholar
• Cancer and IgE. Introducing the concept of AllergoOncology. Penichet M, Jensen-Jarolim E (Eds). Humana Press, NY, USA (2010).
   Google Scholar